Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IV...
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 portion. The safety run-in phase will be used to evaluate the efficacy and safety of sacituzumab tirumotecan at t...
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by ki...
HPV Vaccine, Imiquimod, and Metformin Combination Trial
The goal of this clinical trial is to explore whether additional treatments can help strengthen the participant's immune system to fight cancer caused by the Human Papillomavirus (HPV), a virus spread...
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV). The main q...
Dostarlimab and Cobolimab in Advanced Cervical Cancer
This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer....
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
The researchers are doing this study to find out if ivonescimab is an effective treatment for people with endometrial cancer (EC) and/or cervical cancer (CC). The researchers will also look at whether...
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
This randomized trial will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab compared to pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metasta...
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
This phase I/II trial tests the safety and effectiveness of receiving external beam radiation therapy (EBRT) and brachytherapy along with chemotherapy, consisting of cisplatin and paclitaxel, and immu...
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is...
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile...
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregion...
Top Cities for Cervical Cancer Clinical Trials
Cervical Cancer clinical trials are recruiting across 41 cities. Here are the cities with the most active studies:
About Cervical Cancer
Cervical cancer develops in the cervix and is primarily caused by persistent HPV infection. It is one of the most preventable cancers through HPV vaccination and screening. Treatment includes surgery, radiation, chemotherapy, and immunotherapy for advanced cases.
Clinical trials are advancing new treatments for cervical cancer. Currently, 12 studies are recruiting a combined 2,010 participants across the United States. Research is being conducted by 11 organizations including AstraZeneca, Merck Sharp & Dohme LLC, Pfizer and 8 others.
2026 Cervical Cancer Research Landscape
As of March 2026, the cervical cancer clinical trial landscape includes 12 actively recruiting studies across 41 cities in the United States. These studies are collectively seeking 2,010 participants, with an average enrollment target of 168 per study.
Research is being led by 11 different organizations, including AstraZeneca, Merck Sharp & Dohme LLC, Pfizer, Baylor College of Medicine, Theravectys S.A., and 6 others. The large number of sponsors reflects significant research interest and investment in cervical cancer treatment advancement.
Geographically, cervical cancer trials are most concentrated in Orlando, Florida (4 trials); New Brunswick, New Jersey (4 trials); Miami Beach, Florida (3 trials); Phoenix, Arizona (2 trials); Tucson, Arizona (2 trials) and 7 other cities.
Featured Cervical Cancer Studies
Highlighted recruiting studies for cervical cancer, selected by enrollment size and research scope.
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 portion. The safety run-in phase will be used to evaluate the efficacy and safety of sacituzumab tirumotecan at the dose for evaluation in the Phase 3 portion. The purpose of this study is to compare the efficacy and safety of sacituzumab tirumotecan versus treatment of physician's choice as second-line treatmen...
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to learn about possible side effects of TIVDAK, specially to any side effect that is related to the eye. A side effect is...
Frequently Asked Questions About Cervical Cancer Clinical Trials
Are there cervical cancer clinical trials near me?
Yes, there are 12 cervical cancer clinical trials currently recruiting across 41+ cities in the United States, including Orlando, Florida; New Brunswick, New Jersey; Miami Beach, Florida. Browse the studies above to find one at a location convenient for you.
How do I join a cervical cancer clinical trial?
To join a cervical cancer clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are cervical cancer clinical trials free?
Yes, participation in cervical cancer clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of cervical cancer treatments are being studied?
Current cervical cancer clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 11 research organizations.
Is it safe to participate in cervical cancer clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 2, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 2, 2026 · Data from ClinicalTrials.gov